Company Overview - Pharvaris is a late-stage pre-commercial biotech company currently in Phase III clinical trials for two products targeting HAE (Hereditary Angioedema) attacks [2] - The two products include deucrictibant IR (immediate-release) for on-demand treatment and an extended-release formulation for prevention [2] Upcoming Catalysts - The company anticipates reading out results from its first Phase III trial for on-demand treatment by the end of the year [3] - A filing for the immediate-release product is expected in the first half of 2026 [3] - The readout for the second Phase III trial focused on prophylaxis is scheduled for the second half of the year [3]